| Literature DB >> 24292450 |
K Lavelle1, A M Sowerbutts1, N Bundred2, M Pilling1, L Degner1, C Stockton2, C Todd1.
Abstract
BACKGROUND: Older women have lower breast cancer surgery rates than younger women. UK policy states that differences in cancer treatment by age can only be justified by patient choice or poor health.Entities:
Mesh:
Year: 2013 PMID: 24292450 PMCID: PMC3915115 DOI: 10.1038/bjc.2013.734
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Control preferences scalea
| A | The patient made the final decision about which treatment she would receive. | I made the final decision about which treatment I would receive. |
| B | The patient made the final decision about which treatment she would receive after seriously considering my opinion. | I made the final decision about |
| C | I shared responsibility with the patient for making the final decision about the treatment she would receive. | My doctor and I shared responsibility for deciding which treatment was best for me. |
| D | I made the final decision about which treatment the patient would receive after seriously considering the patient's opinion. | My doctor made the final decision about which treatment would be used but seriously considered my opinion. |
| E | I made the final decision about which treatment the patient would receive. | My doctor made the final decision about which treatment I would receive |
Degner et al (1997).
Janz .
Modified from Janz .
‘Selection of' changed to ‘decision about' to correspond more closely with other responses and scales.
‘All the decisions regarding my treatment' changed to ‘ the final decision about which treatment I would receive' to correspond more closely with Physicians Perception Scale and to avoid patient confusion, that is, referring to the treatment decision for surgery vs no surgery not the treatment decision for type of surgery.
Figure 1Recruitment and retention of patients in the study.
Socio-demographics, and role in surgical decision, by surgery
| Age group (years) | 70–74 | 275 | 34.4 | 257 | 93.5 | |
| 75–79 | 236 | 29.5 | 201 | 85.2 | ||
| 80–84 | 151 | 18.9 | 127 | 84.1 | ||
| | 85+ | 138 | 17.3 | 79 | 57.3 | |
| Socio-economic classification | Professional | 421 | 52.6 | 358 | 85.0 | |
| Intermediate | 198 | 24.8 | 169 | 85.4 | ||
| Manual | 171 | 21.4 | 131 | 76.6 | ||
| | Missing | 10 | 1.3 | 6 | 60.0 | |
| Ethnicity | White | 769 | 96.1 | 643 | 83.6 | |
| Other | 18 | 2.3 | 14 | 77.8 | 0.519 | |
| | Missing | 13 | 1.6 | 7 | 53.9 | |
| Hospital type | Teaching/Uni | 330 | 41.3 | 287 | 87.0 | |
| | District | 470 | 58.8 | 377 | 80.2 | |
| Patient's view of their role in decision: | Active/collab | 183 | 22.9 | 124 | 67.8 | |
| surgery | Passive | 98 | 12.3 | 64 | 65.3 | |
| Not discussed | 499 | 62.4 | 460 | 92.2 | ||
| | Missing | 20 | 2.5 | 16 | 80.0 | |
| Surgeon's view of patient's role in | Active/collab | 292 | 52.8 | 224 | 76.7 | |
| decision: surgery | Passive | 52 | 9.4 | 41 | 78.9 | |
| (base for % | Not discussed | 136 | 24.6 | 129 | 94.9 | |
| Missing | 73 | 13.2 | 59 | 80.8 | ||
| | Not includedd | 247 | na | na | na | |
Abbreviation: CPS=Control Preferences Scale.
*P-values for each variable for complete data reported first followed by data including missings if relevant. P-values <0.05 are shown in bold.
χ2 squared test for trend.
χ2 squared Pearson.
Fisher's exact test.
Surgeons' views only taken in the nested study.
Patients' vs surgeons' views of patient's role in decision to have surgery or not
| Active/collaborative | 8 | 9 | 143 | |
| Passive | 37 | 15 | 63 | |
| Not discussed | 123 | 32 | 267 | |
| Total | 286 | 51 | 136 | 473 |
Agreement=52.6%, Kappa=0.261, P<0.001. Agreed values shown in bold italics.
Tumour characteristics at diagnosis by surgery
| Stage | I | 334 | 41.8 | 293 | 87.7 | |
| | II and IIIa | 466 | 58.3 | 371 | 79.6 | |
| Nodes involved | Yes | 239 | 29.9 | 197 | 82.4 | |
| | No/NR | 561 | 70.1 | 467 | 83.2 | 0.778 |
| Tumour size | ⩽20 mm | 431 | 53.9 | 374 | 86.8 | |
| >20⩽50 mm | 329 | 41.1 | 260 | 79.0 | ||
| >50 mm | 22 | 2.8 | 15 | 68.2 | ||
| | Missing | 18 | 2.3 | 15 | 83.3 | |
| Grade | 1 | 138 | 17.3 | 112 | 81.2 | |
| 2 | 428 | 53.5 | 348 | 81.3 | ||
| 3 | 168 | 21.0 | 145 | 86.3 | 0.213 | |
| | Missing | 66 | 8.3 | 59 | 89.4 | 0.220 |
| Oestrogen receptor ER status | Positive | 667 | 84.6 | 549 | 81.1 | |
| Negative | 85 | 10.6 | 79 | 92.9 | ||
| | Missing | 38 | 4.8 | 36 | 94.7 | |
| Progesterone receptor PR status | Positive | 523 | 65.4 | 417 | 79.7 | |
| Negative | 188 | 23.5 | 166 | 88.3 | ||
| | Missing | 89 | 11.1 | 81 | 91.0 | |
| ER or PR positive | Yes | 684 | 85.5 | 555 | 81.1 | |
| No | 72 | 9.0 | 68 | 94.4 | ||
| | Missing | 44 | 5.5 | 41 | 93.2 | |
Abbreviations: ER=oestrogen receptor; PR=progesterone receptor; NR=not reported. P-values <0.05 are shown in bold.
*P-values for each variable for complete data reported first followed by data including missings if relevant.
Includes 17 patients with stage IIIa.
χ2 squared test for trend.
χ2 squared Pearson.
Fisher's exact test.
Health measures by age and surgery
| ELPHS ADL self report 1–4 inc=worse | 70–74 | 1.44 (1.37–1.51) | Yes | 1.57 (1.52–1.62) | ||
| 75–79 | 1.72 (1.63–1.81) | No | 2.42 (2.30–2.55) | <0.001 | ||
| 80–84 | 1.77 (1.66–1.87) | |||||
| | 85+ | 2.20 (2.07–2.32) | <0.001 | | | |
| SF12 PCS self report 1–100 inc=better | 70–74 | 46.83 (45.38–48.28) | Yes | 45.02 (44.10–45.95) | ||
| 75–79 | 42.59 (40.84–44.33) | No | 32.43 (30.15–34.70) | <0.001 | ||
| 80–84 | 41.47 (39.53–43.40) | |||||
| | 85+ | 37.88 (35.63–40.13) | <0.001 | | | |
| EORTC QLQ self report 1–100 inc=better | 70–74 | 72.59 (70.12–75.05) | Yes | 69.83 (68.13–71.52) | ||
| 75–79 | 63.93 (60.41–67.44) | No | 48.23 (43.67–52.79) | <0.001 | ||
| 80–84 | 63.41 (59.74–67.09) | |||||
| | 85+ | 61.89 (57.75–66.04) | <0.001 | | | |
| PS self report 0–4 categories, inc=worse, %>1 | 70–74 | 20.97 (16.06–25.89) | Yes | 26.36 (22.95–29.77) | ||
| 75–79 | 31.90 (25.85–37.94) | No | 63.36 (55.00–71.72) | <0.001 | ||
| 80–84 | 36.99 (29.06–44.91) | |||||
| | 85+ | 52.67 (44.01–61.34) | <0.001 | | | |
| 6CIT (0–28) inc=worse, %>7 i.e., mild/mod cog impair | 70–74 | 10.89 (7.06–14.73) | Yes | 12.79 (10.10–15.49) | ||
| 75–79 | 12.02 (7.56–16.48) | No | 25.00 (16.54–33.46) | 0.002 | ||
| 80–84 | 13.85 (7.83–19.86) | |||||
| | 85+ | 30.10 (21.09–39.11) | <0.001 | | | |
| Body mass index | 70–74 | 28.46 (27.76–29.17) | Yes | 27.90 (27.48–28.31) | ||
| 75–79 | 28.25 (27.49–29.00) | No | 26.60 (25.50–27.69) | 0.006 | ||
| 80–84 | 27.29 (26.56–28.02) | |||||
| | 85+ | 25.54 (24.70–26.38) | <0.001 | | | |
| Smoking status (% non-smokers) | 70–74 | 87.96 (84.08–91.83) | Yes | 92.15 (90.09–94.20) | ||
| 75–79 | 88.94 (84.90–92.98) | No | 84.09 (77.77–90.41) | 0.007 | ||
| 80–84 | 96.67 (93.76–99.57) | |||||
| | 85+ | 93.33 (89.07–97.60) | 0.008 | | | |
| Charlson co-morbidity, %⩾1 | 70–74 | 41.09 (35.24–46.94) | Yes | 43.98 (40.19–47.76) | ||
| 75–79 | 51.27 (44.85–57.69) | No | 67.65 (59.68–75.61) | <0.001 | ||
| 80–84 | 50.99 (42.93–59.06) | |||||
| 85+ | 52.90 (44.47–61.33) | 0.016 |
Abbreviations: 6CIT=6-Item Cognitive Impairment Test (scale 0–28: increase indicates worse cognitive impairment, 0–7 indicates normal); ECOG-PS=Eastern Co-operative Oncology Group – Performance Status (0–5 categories indicate decreasing functional status); ELPHS ADL=Elderly Population Health Status Survey's Activity of Daily Living (scale 1–4: increase indicates worse functional status); EORTC QLQ-C30=European Organization for Research on Treatment of Cancer Quality of Life Questionnaire (version 3) Global Quality of Life scale 1–100 (increase indicates better health related quality of life); SF-12=Short Form-12 Physical Component Summary (scale 1–100: increase indicates better health status).
Values for scores are mean (95% confidence interval) unless indicated otherwise.
Mann–Whitney.
Kruskal–Wallis χ2.
Fisher's exact.
χ2 for trend.
All P-values are <0.05.
Multivariable (main) logistic regression of receiving primary surgery (vs not receiving primary surgery) (n=674)
| 70–74 | (ref) | — | — | (ref) | — | — |
| 75–79 | 0.40 | 0.22–0.73 | 0.69 | 0.32–1.50 | 0.354 | |
| 80–84 | 0.37 | 0.19–0.71 | 0.54 | 0.24–1.20 | 0.131 | |
| 85+ | 0.09 | 0.05–0.17 | < | 0.21 | 0.10–0.46 | < |
| Active/collab | (ref) | — | — | (ref) | — | — |
| Passive | 0.90 | 0.53–1.50 | 0.677 | 0.89 | 0.44–1.81 | 0.750 |
| Not discussed | 5.61 | 3.58–8.81 | < | 3.54 | 1.97–6.37 | < |
| 0 | (ref) | — | — | (ref) | — | — |
| 1+ | 0.38 | 0.25–0.55 | < | 0.61 | 0.36–1.05 | 0.075 |
| EORTC QLQ 1–100 scale inc=better | 1.04 | 1.03–1.05 | <0.001 | 1.02 | 1.01–1.03 | 0.005 |
| ELPHS ADL 1–4 scale inc=worse | 0.20 | 0.15–0.27 | < | 0.36 | 0.24–0.55 | < |
| Smoker | (ref) | — | — | (ref) | — | — |
| Non-smoker | 2.22 | 1.29–3.83 | 2.60 | 1.18–5.73 | ||
| Positive | (ref) | — | — | (ref) | — | — |
| Negative | 3.95 | 1.42–11.03 | 2.82 | 0.86–9.25 | 0.086 | |
| Tumour size (mm) | 0.98 | 0.97–1.00 | 1.00 | 0.98–1.02 | 0.695 | |
Abbreviations: CI=confidence interval; CPS=Control Preferences Scale; ELPHS ADL=Elderly Population Health Status Survey's Activity of Daily Living; EORTC QLQ=European Organization for Research on Treatment of Cancer Quality of Life Questionnaire; ER=oestrogen receptor; PR=progesterone receptor.
Health measures 6CIT, BMI and ECOG performance status were not included as there was no significant effect in the initial multivariable model. SF12 PCS was removed as it produced VIFs>10. Tumour stage, nodal status, socio-economic classification and type of hospital treated at were removed as they did not significantly improve the fit of the model.
Adjusted for all other variables in the table.
All variance inflation factors <10.
Goodness of fit test χ2 Hosmer–Lemeshow=5.88: d.f.=8; P=0.661.
Area under receiver operator characteristics curve=0.871.
*P-values <0.05 are shown in bold.
Multivariable (nested) logistic regression of receiving primary surgery (vs not receiving primary surgery) adjusting for surgeons' views on role of patient in surgical decision (n=473)
| 70–74 | (ref) | — | — | (ref) | — | — |
| 75–79 | 0.40 | 0.22–0.73 | 0.60 | 0.25–1.48 | 0.267 | |
| 80–84 | 0.37 | 0.19–0.71 | 0.48 | 0.19–1.21 | 0.118 | |
| 85+ | 0.09 | 0.05–0.17 | 0.18 | 0.07–0.44 | ||
| Active/collab | (ref) | (ref) | — | — | ||
| Passive | 0.90 | 0.53–1.50 | 0.677 | 0.70 | 0.30–1.62 | 0.404 |
| Not discussed | 5.61 | 3.58–8.81 | 2.69 | 1.34–5.39 | ||
| Active/collab | (ref) | — | — | (ref) | — | — |
| Passive | 1.31 | 0.55–2.32 | 0.736 | 0.64 | 0.24–1.66 | 0.355 |
| Not discussed | 5.59 | 2.49–12.55 | 2.37 | 0.93–6.04 | 0.072 | |
| ELPHS ADL 1–4 scale inc=worse | 0.20 | 0.15–0.27 | 0.23 | 0.15–0.35 | ||
Abbreviations: CI=confidence interval; CPS=Control Preferences Scale.
Co-morbidity, ER/PR and tumour size were not included as there was no significant effect in the main multivariable model. ELPHS ADL was retained as it showed the strongest effect among the health measures with significant effect in the main model. EORTC QLQ and smoking status were therefore not included.
Adjusted for all other variables in the table.
All variance inflation factors <10.
Goodness of fit test χ2 Hosmer–Lemeshow=10.90: d.f.=8; P=0.208.
Area under receiver operator characteristic curve=0.869. *P-values <0.05 are shown in bold.